Icahn makes fresh inroads at Biogen and Genzyme

Anyone looking for a close-up look at what Genzyme's Henri Termeer was looking to avoid when he struck a deal to amicably seat two of Carl Icahn's representatives on the board need only look at yesterday's brief annual meeting at Biogen Idec. The Biogen board cheerfully welcomed a third ally of Icahn's during the meeting, which was conducted without James Mullen, who retired from his CEO's post on Tuesday. A year ago the Biogen meeting ended in turmoil, breaking up with no clear idea of...